GÖTTINGEN, Germany,
March 25, 2022 /PRNewswire/ -- At
today's virtual Annual General Shareholders' Meeting, the
shareholders of Sartorius AG granted discharge to the
Executive Board and the Supervisory Board and approved the
boards' proposals by a large majority. They passed the resolution
to pay dividends of 1,26 euros per
preference share and 1.25 euros per
ordinary share. The total amount disbursed will be
85.9 million euros. In the previous year, dividends were
0.71 euros per preference share and 0.70 euros per ordinary share.
During the regular election of shareholder representatives to
the Supervisory Board, shareholders re-elected Prof. David Raymond Ebsworth, Dr. jur. Daniela Favoccia, Dr. Lothar Kappich, Ms.
Ilke Hildegard Panzer, and Prof. Dr.
Klaus Rüdiger Trützschler. As Prof. Dr. Thomas Scheper was no longer available for a
further term of office, the Annual General Shareholders' Meeting
elected digital expert Frank
Riemensperger to the Supervisory Board as a shareholder
representative. Riemensperger, who holds a degree in computer
science, held senior management positions at the consulting company
Accenture for many years. The new Supervisory Board will serve for
a term of five years.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language release. Sartorius shall not assume
any liability for the correctness of this translation. The original
German release is the legally binding version.
Additional documents for the Annual General Shareholders'
Meeting 2022:
https://www.sartorius.com/en/company/investor-relations/sartorius-ag-investor-relations/shareholders-meeting
Additional links
Annual Report 2021
Current image files
Financial calendar
April
21, 2022: Publication of first-quarter figures (January
to March 2022)
July 21, 2022: Publication of
first-half figures (January to June
2022)
October 19, 2022: Publication of
nine-month figures (January to September
2022)
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2021, the company earned sales revenue of
some 3.45 billion euros. At the end
of 2021, nearly 14,000 people were employed at the Group's
approximately 60 manufacturing and sales sites, serving customers
around the globe.
Follow Sartorius on Twitter @Sartorius_Group and on
LinkedIn.
Logo -
https://mma.prnewswire.com/media/1696516/Sartorius_Logo.jpg
For any questions please contact:
Timo Lindemann
timo.lindemann@sartorius.com
+49 1709642070
View original content to download
multimedia:https://www.prnewswire.com/news-releases/resolutions-of-the-annual-general-shareholders-meeting-of-sartorius-ag-301510838.html
SOURCE Sartorius AG